Quick Answer
Cyclerion Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $3.24 million for the year ending 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +0.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Cyclerion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Cyclerion Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 96.6%.
- Historical annual values: Fiscal year 2025: $3.24 million | Fiscal year 2024: $3.23 million | Fiscal year 2023: $7.57 million | Fiscal year 2022: $13.38 million | Fiscal year 2021: $53.96 million | Fiscal year 2020: $54.40 million | Fiscal year 2019: $94.90 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: